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1. Introduction
Neurological disorders (ND) are diseases of the central or peripheral nervous 
system. In other words, they affect the brain, spinal cord, cranial nerves, periph-
eral nerves, nerve roots, vegetative nervous system, neuro-muscular junction, 
and muscles. These disorders include epilepsy, Alzheimer’s disease and other 
dementias, cerebrovascular diseases including stroke, migraine and other head-
aches, multiple sclerosis, Parkinson’s disease, nervous system infections, brain 
tumors, traumatic nervous system disorders such as head injuries, and neurologi-
cal disorders related to malnutrition. The result of these imbalances is that human 
voluntary daily life movement is affected. In fact, the achievement of the human 
voluntary movement seemingly simple rather it is considerably complex. As it is a 
very complex mechanism which allows many nerve structures to make decisional 
and/or reflexional choices. Then this mechanism “defines” and “controls” the 
movement, through the nerve impulses intended for the musculoskeletal system. 
It is also known that ND are the main cause of disability and the second cause of 
death in the world [1–4]. Some approaches and relationships about the ND are 
presented Figure 1.
The etiology of ND is very varied due to complexity of nervous system. Among 
the causes of ND there are: lifestyle, infections, genetics, food and/or environmen-
tal influences. Genetic, epigenetic, and various external factors, such as physical 
trauma, infection, and different aspects of the environmental surroundings can be 
involved with the initiation and the progression of the ND. Hormonal, immune, 
and molecular/cellular pathways impact the clinical presentation of the ND involv-
ing various systems [5]. Moreover, gut dysbiosis (microbiota dysregulation) has 
been associated with some neurodegenerative diseases [6]. ND can negatively 
influence the bone physiology favoring decrease of the bone mineral density and 
bone mineral content, altered bone microarchitecture, and decrease bone strength, 
contributing to the development of osteopenia/osteoporosis and increased of risk 
of fracture [5].
The neurodegeneration is presented in several ND [6]. This condition occurs 
when the nervous system or neuron loses its structure, function, or both, leading to 
progressive degeneration or the death of neurons, and well-defined associations of 
tissue system, resulting in clinical manifestations. Studies have been reported that the 
neuroinflammation precede neurodegeneration in various ND [5]. In this context, 
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appears that matrix metalloproteinases have a crucial role in the progression of ND 
related to neurodegeneration, although the etiology and potential causes remain 
widely indefinable [7].
According to the type of ND and the specific affected area, the symptoms are 
presented. The symptoms can be: i) complete or partial paralysis, ii) muscle weak-
ness, iii) partial or complete loss of sensitivity, iv) convulsions, v) headache, vi) 
pain without apparent causes, vii) poor coordination and viii) reduced state of 
consciousness [8]. They can be individually observed or together. As the nervous 
system is strongly related of the behavior, some neurological diseases also manifest 
themselves with emotional or behavioral changes. In this context, the symptoms 
can be sudden changes in mood, or sudden outbursts of anger, depression, altered 
memory, hallucinations, sleep disorders, mental confusion, among others [9].
The evaluation in ND can identify signs that suggest alteration of the nervous 
system and can indicate the most appropriate complementary examinations to 
stablish an accurate diagnosis. Among the complementary exams there are: i) imag-
ing studies [10–13] (such as Magnetic Resonance Imaging, Computed Tomography, 
positron emission tomography, Ultrasonography and Doppler); ii) physiological 
studies (such as neurophysiological examinations [14]: electroencephalogram, 
electroneuromyography, evoked potentials); iii) neuropsychological tests (tests 
that involve interviews, questionnaire applications and specific tests, with the aim 
of testing areas such as attention, memory, language, reasoning, and learning); iv) 
analysis of cerebrospinal fluid; v) blood tests (including genetic tests, research of 
therapeutic levels of drugs in the body, tests for specific antibodies, and general 
tests for numerous other diseases that can cause neurological symptoms); and vi) 
biopsies (of nervous tissue, skin, or muscles). The rapid and accurate diagnosis of 
ND allows for early treatment, improving the quality of life and the prognosis of the 
disease, often being the difference between life and death [15].
ND are multifactorial and can affect several areas of functionality and if left 
untreated, they can result in serious consequences. The evolution and the results are 
depending on the severity of the disease, the type of the disease, the time between 
onset of symptoms and treatment, among other factors. Thus, the treatment of ND 
can involve medication, surgeries, multidisciplinary interventions, and other types 
Figure 1. 










Neurological disorder Definition/Etiology/Prevalence Signals and symptoms
Multiple sclerosis 
[17–19]
It is considered as the most prevalent chronic inflammatory disease of the central 
nervous system associated with inflammatory demyelination and astroglial 
activation, where the neuronal and axonal injury as the leading factors of 
disability. Young individuals (20 to 40 years old), generally, are more affected, 
and late-onset multiple sclerosis characterized when symptoms initiating after 
50 years. About 2,500,000 individuals have multiple sclerosis in worldwide.
The symptoms are different for each person, depending on location of neural 
injury in the body. The most common are fatigue, vision problems, failure to 
control the bladder and loss of balance. The demyelinating lesions in the brain 
and spinal cord contributions to progressive disability, impacting negatively on 
the daily physical and social activities, and cognition.
Alzheimer disease 
[20–22]
It is the most cause of dementia (60–80% of dementia cases), with clinical 
presentation of progressive anterograde episodic memory impairment, affecting 
memory, thinking and behavior. Generally, most people with Alzheimer’s are 65 
and older. The early-onset Alzheimer’s occur when affect individuals under the 
65 years. It is the sixth leading cause of death in the United States and its worldwide 
prevalence is estimated in 24 million.
The early symptom is related the difficulty remembering newly learned 
information. The symptoms can grow severe and interfere with daily tasks, 
including disorientation, mood and behavior changes, confusion about events, 
time and place, unfounded suspicions about family, friends and professional 
caregivers, and difficulty speaking, swallowing, and walking.
Parkinson disease 
[23, 24]
It is a neurodegenerative disorder that affects dopamine-producing neurons in 
the substantia nigra. It is the second most common neurodegenerative disease 
worldwide, leading to significant physical, mental, social, and financial burden 
on patients and caregivers. According to the increase in age, the incidence of it 
increases too, however, four percent of people are diagnosed before age 50. It is 
estimated that more than 10 million people worldwide are living with Parkinson 
Disease.
The cardinal features are resting tremor, cogwheel rigidity, bradykinesia, and 
postural instability, often preceded by prodromal symptoms such as autonomic 
dysfunction appearing 5 to 20 years earlier. Generally, the symptoms develop 
slowly over years, differing from one person to another due to the diversity of 
the disease.
Cerebral palsy [25, 26] It is a complex motor disorder at the level of the central nervous system caused 
by irreversible brain lesions that occur before, during or shortly after birth. It is 
the most common physical disability in childhood. It affects people in different 
ways that can compromise body movement, muscle control, muscle coordination, 
muscle tone, reflex, posture, and balance. Cerebral palsy is a permanent life-long, 
but some of these signs can improve or worsen over time.
Cerebral palsy has a prevalence of 1 in 700 live births, affecting about 18 million 
people worldwide.
It is common the presence of reduction in the motor repertoire of gestures and 
a loss in the quality of movement with reduction of normal motor patterns. The 
postures which the child adopt and maintain, as well as their stability, is altered: 
the child has difficulty in both moving and staying still. The more alterations 








Neurological disorder Definition/Etiology/Prevalence Signals and symptoms
Autism spectrum 
disorder [27, 28]
It is a neurodevelopmental disorder characterized by deficits in social 
communication and the presence of restricted interests and repetitive behaviors. 
This neurobiological disorder influenced by both genetic and environmental 
factors affecting the developing brain. It is estimated about 1.68% of United 
States children aged 8 years (or 1 in 59 children) are diagnosed with ASD and this 
estimate can be extrapolated to the worldwide.
Considering behavior, these individuals can present aggression, self-mutilation, 
crying, lack of eye contact, shouting, hyperactivity, involuntary imitation 
of someone else’s movements, impulsivity, inappropriate social interaction, 
irritability, repetitive movements, repetition of meaningless words, 
meaningless repetition of the words themselves or persistent repetition of 
words or actions; related to the development, they can present speech delay in a 
child or learning disability; about cognition, can be presented lack of attention 
or intense interest in a limited number of things; considering psychological 
symptoms, they can present depression or ignores the emotions of others; in 
speech, they can present speech disorder or loss of speech. These individuals 
can also present tiptoeing, anxiety, lack of empathy, sensitivity to sound or tic.
Amyotrofic lateral 
sclerosis [29, 30]
It is characterized as a progressive neurodegenerative disease that affects nerve 
cells in the brain and the spinal cord, affecting controlling voluntary muscle 
movement compromising movements like chewing, walking, and talking. As 
this disease is progressive, the symptoms get worse over time. The prevalence is 
estimated in 5 per 100,000 in the United States; being about 30,000 individuals 
present this condition.
The common symptoms are fasciculations (muscle twitches) in the arm, leg, 
shoulder, or tongue, muscle cramps, tight and stiff muscles (spasticity), muscle 
weakness affecting an arm, a leg, neck, or diaphragm, slurred and nasal speech, 
difficulty chewing or swallowing.
Myastenia graves 
[31–34]
It is an autoimmune disorder of neuromuscular transmission, characterized as an 
error in the transmission of nerve impulses to muscles, that promote fluctuating 
weakness and disabling fatigability. The prevalence is estimated in approximately 
20 cases per 100,000 population, affecting twice as many women as men, 
however, considering older individuals, men appear are affected more often.
The mainly symptom is muscle weakness that worsens after periods of activity 
and improves after periods of rest. Muscles such as those that control eye and 
eyelid movement, facial expression, chewing, talking, and swallowing are 
compromised, generally, but not always. The symptoms that ca be presented are 
ocular myasthenia, ptosis, diplopia, dysarthria, weakness in the arms, hands, 
fingers, legs, and neck. The severe weakness of myasthenia gravis may cause 
respiratory failure.
Spinal cord injury 
[35, 36]
It is often the result of an unpredictable accident or violent event. This condition is 
frequently associated with severe clinical-neurological deficits leading to persisting 
physical and psychological sequela. It can be caused by: a violent attack (as a 
stabbing or a gunshot), diving into water that’s too, shallow and hitting the bottom
trauma during a car accident (as a trauma to the face, head, and neck region, back, 
or chest area), falling from a significant height, head, or spinal injuries (as during 
sporting events), and electrical accidents.
It is estimated that 327 million people are affected with this condition annually
The symptoms can be related to difficulty in walking, loss of control of the 
bladder or bowels, inability to move the arms or legs, feelings of spreading 
numbness or tingling in the extremities, headache, pain, pressure, and stiffness 










Neurological disorder Definition/Etiology/Prevalence Signals and symptoms
Traumatic Brain Injury 
[37, 38]
It is characterized as a damage in the brain by an external mechanical force, 
leading to temporary/permanent secondary injuries. This alteration can promote 
impairment of cognitive, physical, and psycho-social functions with altered 
consciousness. The mainly mechanism responsible for neuronal damage in this 
condition is an increase in oxidative reactions initiated by free radicals generated 
by the injury. It is considered as a leading cause of mortality, morbidity, and 
disability worldwide, and it is estimated that 5.3 million of individuals in United 
States (2 percent of the population) present a disability as a result of a traumatic 
brain injury.
The signs and symptoms related to mild traumatic brain injuries are: physical 
symptoms (headache, nausea or vomiting, fatigue or drowsiness, problems 
with speech, dizziness or loss of balance, sensory symptoms, sensory problems 
- such as blurred vision, ringing in the ears, a bad taste in the mouth or changes 
in the ability to smell
Sensitivity to light or sound; cognitive, behavioral, or mental symptoms; 
loss of consciousness for a few seconds to a few minutes; without loss of 
consciousness, but a state of being dazed, confused or disoriented; memory or 
concentration problems; mood changes or mood swings; feeling depressed or 
anxious; difficulty sleeping; sleeping more than usual. Considering moderate 
to severe traumatic brain injuries can be present: physical symptoms; loss of 
consciousness from several minutes to hours; persistent headache or headache 
that worsens; repeated vomiting or nausea; convulsions or seizures; dilation 
of one or both pupils of the eyes; clear fluids draining from the nose or ears; 
inability to awaken from sleep; weakness or numbness in fingers and toes; loss 
of coordination; cognitive or mental symptoms; profound confusion; agitation; 
slurred speech; coma and other disorders of consciousness.
Stroke [39, 40] There are 3 types of strokes: ischemic stroke (when blood flow through the artery 
to the brain becomes blocked, such as blood clots); hemorrhagic stroke (when 
an artery in the brain breaks and puts too much pressure on brain cells damaging 
them, that can be intracerebral hemorrhage or subarachnoid hemorrhage); and 
transient ischemic attack (when blood flow to the brain is blocked for only a short 
time—usually no more than 5 minutes). The ischemic stroke corresponds to 
87% of strokes. More than 795,000 individuals in the United States have a stroke, 
annually.
The symptoms related to this condition can be sudden numbness or weakness 
in the face, arm, or leg, especially on one side of the body; sudden confusion, 
trouble speaking, or difficulty understanding speech; sudden trouble seeing in 
one or both eyes; sudden trouble walking, dizziness, loss of balance, or lack of 
coordination, and sudden severe headache with no known cause.
Table 1. 
Considerations about determined neurological disorders.
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of available treatments to help the improvement of these patients. Among the physi-
cal therapies and other treatments, there are: i) movement, exercise, and physical 
activity therapies to improve the individual’s motor capacity; ii) speech therapy, 
which improves the functioning of swallowing and a language; iii) occupational/
cognitive therapies to stimulate functionality, working on the affected cognitive 
areas, such as memory, verbal and written communication, language, etc.; iv) 
psychotherapy for the treatment of the emotional components of the disease. Drug 
treatments for many ND, such as selective serotonin reuptake inhibitors, antipsy-
chotics, anti-epilepsy drugs have independent and overlapping roles in mediating 
bone loss [5, 16].
In this introductory chapter, some considerations about determined ND will be 
presented and discussed, as indicated in Table 1.
2. General approaches in ND
The functional capacity and quality of life of individuals with ND can be 
affected in different ways according to the injured area, the extension of the injury, 
the time of the injury and the age of the patient. The symptoms associated differing 
to each ND and can be related to impairments in movements, cognition, behavior, 
balance, tonus, bone and spasticity among others [41, 42].
The therapeutical approaches are stablished according to the type of ND and 
evolution of them. These approaches can involve pharmacological and non-phar-
macological interventions, neurological physical therapy, biological and molecular 
approaches, among other that aim to management of the ND, improving function-
ality, daily activities, and quality of life of these individuals [43, 44].
3. Conclusion
It is known that Neurological disorders include all diseases and dysfunctions 
of the central or peripheral nervous system under the same name. It is known that 
Hundreds of millions of people worldwide suffer from neurological disorders. It 
is also known that neurological conditions pose an economic burden to society. 
The purpose of this chapter is to summarize the impact of neurological disorders 
on patients’ quality of life and to acknowledge their importance. This chapter will 
provide a better understanding of neurological disorders, assessments, preven-
tion decisions, medical consultation, and treatments. In our present chapter, it is 
concluded that ND can impact the life of the individual in all aspects and the lesions 
are related to the area, injury, time, and age of them. The therapeutical approaches 
are selected according to type and evolution of ND and involves multidisciplinary 
treatments. These approaches seek to promote a cure or the autonomy of individual 
for a long time as possible with quality of life.
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